Skip to content
  • Home
  • World News
  • Business
  • Aviation
195 news

195News

All the news that's fit to print

  • Home
  • World News
  • Business
  • Aviation
  • Toggle search form
  • First pilgrims’ flights land in Saudi Arabia
    First pilgrims’ flights land in Saudi Arabia World News
  • Smoking Cession Market worth $ 57.72 Billion by 2030
    Smoking Cession Market worth $ 57.72 Billion by 2030 World News
  • St. Lucian Dona Regis-Prosper Named First Female Secretary-General and CEO of the Caribbean Tourism Organization
    St. Lucian Dona Regis-Prosper Named First Female Secretary-General and CEO of the Caribbean Tourism Organization World News
  • Taiwan’s ‘BizWinner 5G XR Expo Solution’ Wins Best Innovation at the London Design Award
    Taiwan’s ‘BizWinner 5G XR Expo Solution’ Wins Best Innovation at the London Design Award World News
  • War Day 50 :: war chronicles with Advisor to Ukraine President, Intel Officer, Alexey Arestovych
    War Day 50 :: war chronicles with Advisor to Ukraine President, Intel Officer, Alexey Arestovych World News
  • DLS Technology is named Citrix Preferred Partner
    DLS Technology is named Citrix Preferred Partner Aviation
  • Holabird Western Americana Collections’ two-part Marvels of the West auction will be held January 25-26 & January 27-28
    Holabird Western Americana Collections’ two-part Marvels of the West auction will be held January 25-26 & January 27-28 Business
  • Tamil Civil Society Groups Reject “Himalaya Declaration” for Not Addressing Tamil Grievances
    Tamil Civil Society Groups Reject “Himalaya Declaration” for Not Addressing Tamil Grievances World News
2nd Confirmation of Useful Data in Development of mRNA for Treating Cancer: Regen BioPharma, (Stock Symbols: RGBP) $RGBP

2nd Confirmation of Useful Data in Development of mRNA for Treating Cancer: Regen BioPharma, (Stock Symbols: RGBP) $RGBP

Posted on October 28, 2023 By NewsEditor

2nd Confirmation of Useful Data in Development of mRNA for Treating Cancer: Regen BioPharma, (Stock Symbols: RGBP) $RGBP

Regen BioPharma Stock Symbol: RGBP

Regen BioPharma Stock Symbol: RGBP $RGBP

Regen BioPharma Product Pipeline RGBP $RGBP

Regen BioPharma Product Pipeline RGBP $RGBP

Regen BioPharma Patents RGBP $RGBP

Regen BioPharma Patents RGBP $RGBP

Regen BioPharma Scientific Advisory Board RGBP $RGBP

Regen BioPharma Scientific Advisory Board RGBP $RGBP

Second Contract Research Organization Confirms Extremely Useful Data in Development of mRNA and Small Molecule Immunotherapies : (Stock Symbols: RGBP) $RGBP

Regen BioPharma Inc. (OTCMKTS:RGBP)

“Having a second confirmatory study gives us confidence we are making the right decision to pursue these novel cell therapies focused on autoimmunity”

— says Dr. David Koos, Chairman and CEO of RGBP

LA MESA, CALIFORNIA, UNITED STATES, October 26, 2023 /EINPresswire.com/ — Second Contract Research Organization Confirms Extremely Useful Data in Development of mRNA and Small Molecule Immunotherapies for Treating Cancer and Autoimmune Disorders: Regen BioPharma, (Stock Symbols: RGBP) $RGBP

 Advancing Therapies for Treating Cancer and Autoimmune Disorders by Modulating the Immune Checkpoint NR2F6.

 Applying a Genetic Approach to Regulating NR2F6 Levels in Human T Cells.

 Additional Work for Blood Disorders, Cellular Immunotherapy, Modulating Key Molecular Processes in Cancer Stem Cells, and Repairing Damaged Bone Marrow.

 Received Unexpected and Potentially Extremely Useful Data on Experimental Studies on the Company’s DuraCAR CAR T-Cell Therapeutic.

 Second Phase Confirmatory Data Received on Duracar CAR-T Cell Therapy Program; Autoimmunity to be Targeted.

 Studies Demonstrated That T Cells that express the Chimeric Antigen Receptor (CAR) Construct Expressing siRNA for NR2F6 can be Successfully Created.

 Second Unrelated qRT-PCR Testing Underway to Determine if NR2F6 mRNA is Elevated or Inhibited by Company’s CAR in T-Cells.

Regen BioPharma, (OTC-PINK: RGBP) and (OTC-PINK: RGBPP) is a biotechnology company working in the immunology and immunotherapy space. RGBP is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, RGBP is developing mRNA and small molecule therapies for treating cancer and autoimmune disorders.

RGBP plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, RGBP is advancing therapies for treating cancer and autoimmune disorders by modulating the immune checkpoint NR2F6. RGBP is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cells through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

RGBP Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program; Autoimmunity to be Targeted

On October 25th RGBP released an announcement covering its previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic

( RGBP recently received unexpected and potentially extremely useful data from one of its contract research organizations (CRO) retained to perform experimental studies on the Company’s DuraCAR CAR T-cell therapeutic. These studies demonstrated that T cells that express the chimeric antigen receptor (CAR) construct expressing siRNA for NR2F6 can be successfully created. https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs-duracar-indicate-potential-suppression-of-autoimmunity-company-retains-contract-research-organization-to-conduct-additional-confirmatory-studies-301931365.html.

RGBP has now received the complete set of confirmatory data performed by a second contract research organization (CRO) which is independent of the CRO that performed the initial experiments. These data confirm that T cells that express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 had high expression levels of NR2F6 mRNA. NR2F6 is considered an immune checkpoint and thus increasing its activity is likely to lead to immune suppression.

“Being able to substantially elevate NR2F6 levels is truly an unexpected, but welcome finding. We now have a sound scientific basis to pursue designing T cells which can tamp down on the uncontrolled immune activation seen in multiple autoimmune disorders,” says Dr. Harry Lander, Chief Scientific Consultant to RGBP. “We recently filed a patent application around such T cells and we feel we have a head start on this in the scientific community, particularly around using nuclear receptors such as NR2F6.”

“Having a second confirmatory study gives us confidence we are making the right decision to pursue these novel cell therapies focused on autoimmunity,” says Dr. David Koos, Chairman and CEO of RGBP. “I expect that after consulting with our Board of Advisors and internally, the Company will soon have a clear picture of the specific indications and approaches it will pursue.”

RGBP Receives First Phase of Confirmatory Study

CAR-T Cells Created

On October 10th RGBP issued an announcement covering its previously discussed initiation of a series of experiments to validate it’s DuraCAR CAR T-cell therapeutic ( while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs-duracar-indicate-potential-suppression-of-autoimmunity-company-retains-contract-research-organization-to-conduct-additional-confirmatory-studies-301931365.html.

RGBP then reported it had received the first set of confirmatory data which demonstrates that T cells that express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 were successfully created. In addition, the siRNA that is designed into the CAR T-cell was very highly expressed. Subsequent RGBP studies will determine if the expression of NR2F6 mRNA is suppressed or enhanced as a result of the high expression of siRNA.

“This is a major accomplishment in moving this model forward into therapies because in order to test whether we can genetically manipulate NR2F6 levels, we have to be able to produce a CAR T-cell where we demonstrate expression of this siRNA,” says Dr. Harry Lander, Chief Scientific Consultant to RGBP. “We are excited to see the results on NR2F6 expression. If it is inhibited, we will focus on using these DuraCAR cells as originally envisioned – to attack solid tumors. If it is enhanced, we will begin re-tooling these cells to treat autoimmune disorders.”

For more information on $RGBP visit: http://www.regenbiopharmainc.com

DISCLAIMER: CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses, and may NOT sell, offer to sell, or offer to buy any security. CAP/FPS/CA’s market updates, news alerts, and corporate profiles are NOT a solicitation or recommendation to buy, sell, or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details that were previously disseminated by the companies mentioned in this release or the opinion of the writer. CAP/FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated $500 by a third party for the dissemination of this article.

SOURCE: CorporateAds.com

David R. Koos, Ph.D.
Regen BioPharma Inc.
+1 619-722-5505
email us here
Visit us on social media:
Twitter
YouTube

Regen BioPharma Inc. (OTC Pink: RGBP) $RGBP

You just read:

News Provided By

October 26, 2023, 14:50 GMT


EIN Presswire’s priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content.
As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone’s Internet News Presswire™,
tries to define some of the boundaries that are reasonable in today’s world. Please see our
Editorial Guidelines
for more information.



Article originally published on www.einpresswire.com as 2nd Confirmation of Useful Data in Development of mRNA for Treating Cancer: Regen BioPharma, (Stock Symbols: RGBP) $RGBP

World News

Post navigation

Previous Post: War Day 90: war diaries w/ Advisor to Ukraine President, Intel Officer @Alexey Arestovych & #Фейгин
Next Post: CloudDefense.AI is going to attend OWASP 2023 Global AppSec in Washington, DC

Related Posts

  • Overseas Schools Advisory Council Meeting, Thursday, January 26, 2023
    Overseas Schools Advisory Council Meeting, Thursday, January 26, 2023 World News
  • War in Ukraine, Analytics. Day 981: It is Not Russia Winning. It’s Ukraine Losing. Arestovych
    War in Ukraine, Analytics. Day 981: It is Not Russia Winning. It’s Ukraine Losing. Arestovych World News
  • Overseas Schools Advisory Council Meeting, Thursday, January 26, 2023
    The United States Releases Signed Memorandum of Understanding with the Democratic Republic of Congo and Zambia to Strengthen Electric Vehicle Battery Value Chain World News
  • Tunisia National Day – United States Department of State
    Tunisia National Day – United States Department of State World News
  • Empty Declarations  (Part2). War in Ukraine, Analytics. Arestovich, Romanenko, Homyak.
    Empty Declarations (Part2). War in Ukraine, Analytics. Arestovich, Romanenko, Homyak. World News
  • War in Ukraine, Analytics. Day 1027: Ukrainian Politics. Covering Rotten with Bright. Arestovych
    War in Ukraine, Analytics. Day 1027: Ukrainian Politics. Covering Rotten with Bright. Arestovych World News
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
« Jun    
last celebrity gossip
Gossip Stone - celebrity life and gossip

Recent Posts

  • Aston University Professor Presents New Research on AI-based Software-Defined Neuromorphic Computing at IEEE CLOUD 2025July 30, 2025
  • Community Action of Napa Valley Opens Outdoor Learning Center & Playground Thanks to CalFire GrantJuly 30, 2025
  • Adaptive Robotics Market to Surge from $5.0 Billion in 2020 to $55.1 Billion by 2030, with a CAGR of 26.3%July 29, 2025
  • Stay in a Historic Palazzo Where Culture Meets Connectivity at Butera 28 ApartmentsJuly 29, 2025
  • The National Trial Lawyers Announces Anne Joynt as a Member of the NTL – Civil PlaintiffJuly 29, 2025
Brand Values Content
VUGA Enterprises - media network PR & Marketing
  • Deputy Secretary Sherman’s Meeting with European External Action Service Secretary General Sannino
    Deputy Secretary Sherman’s Meeting with European External Action Service Secretary General Sannino World News
  • Empath Launches AI-Enabled Opportunity Marketplace: Unlocks Internal Mobility
    Empath Launches AI-Enabled Opportunity Marketplace: Unlocks Internal Mobility Business
  • TV Ears Achieves A+ Rating From BBB
    TV Ears Achieves A+ Rating From BBB Business
  • Cosmetics And Personal Care Packaging Equipment Market Size, Share, Revenue, Trends And Drivers For 2024-2033
    Cosmetics And Personal Care Packaging Equipment Market Size, Share, Revenue, Trends And Drivers For 2024-2033 World News
  • Hypno Challenge Reality Show Coming to Gossip Stone TV
    Hypno Challenge Reality Show Coming to Gossip Stone TV World News
  • Join the 2023 Earth Day Photo Challenge
    Join the 2023 Earth Day Photo Challenge Business
  • Allulose Market will Gain Momentum by 2032 to Surpass 8.2 Million
    Allulose Market will Gain Momentum by 2032 to Surpass $308.2 Million World News
  • Statement of Homeland Security Secretary Mayorkas on the Family Reunification Task Force and the Successful Reunification of More Than 600 Children With Their Families
    Statement of Homeland Security Secretary Mayorkas on the Family Reunification Task Force and the Successful Reunification of More Than 600 Children With Their Families World News
aerospace company
stem cell clinic in kiev
medical spa in miami
Fashion TV free

Copyright © 2023 195 News. All Rights Reserved by Coolaser | Partner of VUGA Enterprises |  Advertising: Get Published

Powered by .